Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna Therapeutics (MDNAF) announced that topline MDNA11 study data will be presented orally at SITC on November 7, 2026.
The Phase 1/2 ABILITY-1 trial evaluates MDNA11 in expansion cohorts of patients with advanced and metastatic gastrointestinal, endometrial and melanoma cancers. Abstract 517 was selected among the meeting's Top 150 Abstracts. Its title describes clinical activity in gastrointestinal malignancies selected using biological markers, with MDNA11 alone and with pembrolizumab, including disease resistant to immune checkpoint inhibitors.
The presentation is scheduled for 4:30–4:45 p.m. MST in Oral Session 3 at the Phoenix Convention Center, Room 301D, in Phoenix, Arizona.
Medicenna Therapeutics (MDNAF) shareholders authorized a potential share consolidation at the annual general and special meeting held October 1, 2026. The board may choose a ratio of one post-consolidation share for every 2 to 20 pre-consolidation shares, or decide not to proceed. Any implementation requires regulatory approvals; the ratio and effective date would be announced once the board decides to proceed.
The company said consolidation could support minimum bid-price compliance for a potential major U.S. exchange listing and attract investors with minimum share-price requirements. A listing would still require satisfaction of all applicable requirements and exchange approval. Shareholders also elected all four director nominees, each with more than 97% support, and reappointed MNP as auditor. 31.82% of outstanding common shares were represented at the meeting.
Medicenna (MDNAF) will present an analysis of bizaxofusp survival outcomes in recurrent glioblastoma at SNO 2026 on November 13.
The analysis concerns unresectable, IDH-wildtype recurrent glioblastoma in the intended Phase 3 population and uses a propensity score-weighted external control arm. Nicholas Butowski is scheduled to give the oral presentation at 10:36 a.m. ET in Philadelphia.
Medicenna Therapeutics (MDNAF) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. President and CEO Dr. Fahar Merchant is scheduled to present on September 16, 2026, from 12:00 PM to 12:30 PM EST at the Lotte New York Palace Hotel.
The presentation will be held in the Kennedy II room on the 4th floor and will be webcast live, with replay access available for 90 days via the investor relations Events & Presentations section of Medicenna’s website. Investors can also request one-on-one meetings with Dr. Merchant through conference registration or their H.C. Wainwright representative.
Medicenna Therapeutics (OTCQX: MDNAF) reported fiscal Q1 2027 results for the quarter ended June 30, 2026, and updated progress across its Superkine pipeline. Cash and cash equivalents were $5.7 million versus $6.3 million on March 31, 2026, boosted by $4.4 million in gross proceeds from a public offering and, subsequent to quarter end, $1.3 million from the Australian R&D incentive program.
The company entered a term sheet for a structured financing with Sorbie that may result in approximately $8.0 million, subject to closing conditions, which, together with existing funds, is expected to support planned spending into calendar Q2 2027. MDNA11’s Phase 1/2 ABILITY-1 enrollment remains on track to complete in Q3 2026, with previously reported response rates in the 30–40% range, and updated data plus bizaxofusp results to be presented in upcoming oral conference sessions. NEO-CYT continues enrolling melanoma patients, and planning is underway for an IND and 2027 Phase 1 trial of MDNA113.
Medicenna Therapeutics (OTCQX:MDNAF) reported fiscal 2026 results and pipeline progress. MDNA11 showed 30–40% response rates in Phase 1/2 ABILITY-1 across difficult solid tumors, with updated data and a Phase 2b strategy expected by late 2026. MDNA113 preclinical data supported IND-enabling studies targeting an IND filing in Q4 2026. Bizaxofusp remains Phase 3–ready for recurrent GBM while partnership discussions continue.
Cash was $6.3M at March 31, 2026, plus a $4.4M unit offering and a Sorbie financing term sheet (up to about $8M, outcome uncertain). Operating costs were $22.4M; net loss was $18.4M (vs $11.8M in 2025).
Medicenna (OTCQX: MDNAF) announced two newly issued U.S. patents and one allowed U.S. patent application covering its IL-4 and IL-13 Superkine platforms, including bizaxofusp, and extending to cellular immunotherapy and CNS tumor combination therapies.
According to Medicenna, its global Superkine patent portfolio now exceeds 100 active granted patents and applications across key markets.
Medicenna (OTCQX: MDNAF) highlighted the NEO-CYT Phase 1b trial of its IL-2 Superkine MDNA11 in frontline neoadjuvant melanoma at ASCO 2026. Up to 80 patients with high-risk resectable melanoma will be randomized across four arms, with major pathologic response as the primary efficacy endpoint. Together with the ongoing ABILITY-1 Phase 1/2 trial in later-line solid tumors, NEO-CYT supports a broader MDNA11 strategy across tumor types and disease stages. According to Medicenna, clinical updates from both studies are anticipated in H2 2026, creating potential future milestones for the program.
Medicenna (OTCQX:MDNAF) reported dosing the first patient in NEO-CYT, an investigator-initiated neoadjuvant Phase 1b trial of MDNA11 in high-risk, surgically resectable Stage III cutaneous melanoma in Italy.
The study evaluates MDNA11 plus nivolumab, with or without ipilimumab, targeting major pathologic response before curative-intent surgery.
Medicenna (MDNAF) announced a poster presentation on the randomized neoadjuvant NEO-CYT Phase 1b trial testing MDNA11 with nivolumab ± ipilimumab in high‑risk, surgically resectable Stage III melanoma at ASCO 2026 in Chicago, May 29–June 3.
Presenter: Paolo Antonio Ascierto, MD; Poster #: 488a; Abstract: TPS9612; Session: Melanoma/Skin Cancers; Date/time: May 31, 9:00 AM–12:00 PM CDT. Trial sponsor: Fondazione Melanoma Onlus. EudraCT ID: 2024-519010-31-00.